Vol 80, No 3 (2022)
Editorial
Published online: 2022-02-18
Cardiac magnetic resonance imaging in heart failure: The added value of tissue characterization
Abstract
Not available
References
- Ojrzyńska-Witek N, Marczak M, Mazurkiewicz Ł, et al. Role of cardiac magnetic resonance in heart failure of initially unknown etiology: A 10-year observational study. Kardiol Pol. 2021 [Epub ahead of print].
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
- Garbi M, Edvardsen T, Bax J, et al. Reviewer panel:. EACVI appropriateness criteria for the use of cardiovascular imaging in heart failure derived from European National Imaging Societies voting. Eur Heart J Cardiovasc Imaging. 2016; 17(7): 711–721.
- Mahrholdt H, Wagner A, Judd RM, et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005; 26(15): 1461–1474.
- Kanagala P, Cheng ASH, Singh A, et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in heart failure with preserved ejection fraction - implications for clinical trials. J Cardiovasc Magn Reson. 2018; 20(1): 4.
- Ferreira VM, Piechnik SK, Robson MD, et al. Myocardial tissue characterization by magnetic resonance imaging: novel applications of T1 and T2 mapping. J Thorac Imaging. 2014; 29(3): 147–154.
- Garg P, Assadi H, Jones R, et al. Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction. Sci Rep. 2021; 11(1): 617.
- Spieker M, Haberkorn S, Gastl M, et al. Abnormal T2 mapping cardiovascular magnetic resonance correlates with adverse clinical outcome in patients with suspected acute myocarditis. J Cardiovasc Magn Reson. 2017; 19(1): 38.
